| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
24035 |
| Drug |
Dupilumab |
| Brand |
Dupixent® |
| Indication |
Dupilumab is indicated in adults as an add-on maintenance treatment for uncontrolled COPD characterised by raised blood eosinophils on a combination of an ICS, a LABA, and a LAMA, or on a combination of a LABA and a LAMA, if an ICS is not appropriate. |
| Rapid review commissioned |
06/09/2024 |
| Rapid review completed |
04/10/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of dupilumab for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE |
30/10/2024 |
| Pre-submission consultation with Applicant |
10/12/2024 |
| Full submission received from Applicant |
06/07/2026 |
| Preliminary review sent to Applicant |
21/09/2026 |
| NCPE assessment re-commenced |
20/10/2026 |
| Follow-up to preliminary review sent to Applicant |
03/11/2026 |
| NCPE assessment re-commenced |
06/11/2026 |
